Apollon Wealth Management LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 20.3% in the ...

Zimmer Biomet recently announced entering a definitive agreement to acquire all outstanding common shares of Paragon 28. Under the agreement, ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Zimmer Biomet beat analysts’ revenue expectations by ...

Stay updated on Zimmer Biomet with Becker's as they report on recent updates, including sales growth, a new acquisition, and a successful surgery.

Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Please go ahead. Thank you, Operator, and good morning, everyone. Welcome to Zimmer Biomet Biomet's fourth quarter 2024 earnings conference call. Joining me on today's call are Iwan Tornos ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...

Zimmer Biomet to acquire Paragon 28 for $13/share, totaling $1.2B in enterprise value. Deal expected to close in H1 2025, with potential $1/share CVR based on 2026 sales milestones. Get real-time ...

When shares of Zimmer Biomet (NYSE:ZBH) moved down to the $105 mark in September, I believed that real value was showing up. Shares sold off despite the projection of mid-single digit sales growth ...

Stock analysts at Roth Capital issued their Q1 2025 earnings estimates for Zimmer Biomet in a research note issued on Friday, February 7th. Roth Capital analyst J. Wittes forecasts that the medical ...